Drugs / Acetylcholine
Acetylcholine
also known as
ACh · ACETYLCHOLINE CHLORIDE · Acetylcholine chloride for injection · ACETYLCHOLINE IODIDE · Chlorure d'acetylcholine · Choline acetate (ester) chloride · Cloruro de acetilcolina · Miochol · +3 more
Small molecule targets CHRM3 via activation
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | MIOCHOL | — | 1973-10-09 | fda.gov ↗ |
Trials 31
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 09 trials | ||||||
| Phase 0 | NCT06520982 | Sep 2024 → Jun 2027 expected | sympathetic nervous system disorder | University of Missouri-Columbia | Recruiting | No outcome recorded |
| Phase 0 | NCT06499844 | Aug 2024 → Aug 2025 overdue | — | University of Iowa | Recruiting | No outcome recorded |
| Phase 0 | NCT05946798 | Aug 2023 → Jun 2027 expected | gestational diabetes | Anna Stanhewicz, PhD | Recruiting | No outcome recorded |
| Phase 0 | NCT05946785 | Jul 2023 → Dec 2026 expected | gestational diabetes | Anna Stanhewicz, PhD | Recruiting | No outcome recorded |
| Phase 0 | NCT05653973 | Jan 2023 → Mar 2027 expected | preeclampsia | Anna Stanhewicz, PhD | Recruiting | No outcome recorded |
| Phase 0 | NCT04001647 | Jun 2019 → Aug 2022 | arterial disorder, isoproterenol-mediated vasodilatation | Colorado State University | Terminated | No outcome recorded |
| Phase 0 | NCT03972683 | Apr 2019 → Jul 2021 | — | Colorado State University | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 0 | NCT03738943 | Feb 2019 → Jun 2021 | — | Colorado State University | Completed | No outcome recorded |
| Phase 0 | NCT04374500 | Jan → Oct 2006 | obesity disorder | Stefan Soderberg | Completed | No outcome recorded |
| Phase 110 trials | ||||||
| Phase 1 | NCT06911372 | Aug 2025 → Apr 2027 expected | gestational diabetes | Anna Stanhewicz, PhD | Recruiting | No outcome recorded |
| Phase 1 | NCT01848301 | Sep 2012 → Sep 2014 | transplant rejection | Gladwin, Mark, MD | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT02833207 | Apr 2012 → Nov 2021 | obesity disorder | University of Wisconsin, Madison | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT01137656 | Apr 2010 → Aug 2013 | — | Mark Gladwin | Completed | No outcome recorded |
| Phase 1 | NCT02966665 | Sep 2008 → Aug 2030 expected | chronic obstructive pulmonary disease, heart failure, pulmonary arterial hypertension | D. Walter Wray | Recruiting | No outcome recorded |
| Phase 1 | NCT00327080 | May 2006 → Mar 2009 | HIV infectious disease | National Heart, Lung, and Blood Institute (NHLBI) | Terminated | No outcome recorded |
| Phase 1 | NCT00264186 | Jun 2005 → ? | — | Medical University of Vienna | Completed | No outcome recorded |
| Phase 1 | NCT00076414 | Jan 2004 → Sep 2005 | — | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
| Phase 1 | NCT00072826 | Nov 2003 → Aug 2007 | sickle cell disease | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
| Phase 1 | NCT00160888 | Nov 1999 → Dec 2006 | — | Heidelberg University | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03953326 | Apr 2019 → Dec 2020 | breast cancer, leukemia, lymphoma | Penn State University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 23 trials | ||||||
| Phase 2 | NCT00508989 | Jul 2007 → Dec 2010 | sickle cell disease | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 2 | NCT00166166 | Jul 2002 → Jan 2013 | hyperlipidemia | Emory University | Terminated | No outcome recorded |
| Phase 2 | NCT00009581 | Jan 2001 → Jan 2003 | sickle cell disease | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
| Phase not applicable8 trials | ||||||
| — | NCT06454084 | Sep 2023 → Dec 2024 | isoproterenol-mediated vasodilatation, mouth disorder | Semmelweis University | Unknown | No outcome recorded |
| — | NCT05193968 | Feb 2022 → Dec 2026 expected | — | Mayo Clinic | Recruiting | No outcome recorded |
| — | NCT04777383 | Apr 2019 → Oct 2021 | vascular disorder | University Hospital, Linkoeping | Terminated | No outcome recorded |
| — | NCT01162824 | Jan → Apr 2011 | atherosclerosis, myocardial ischemia | St George's Healthcare NHS Trust | Unknown | No outcome recorded |
| — | NCT01125943 | Jun 2010 → Oct 2011 | cancer, hypertensive disorder | Radboud University Medical Center | Completed | No outcome recorded |
| — | NCT00901719 | Apr → May 2010 | heart failure | University of Edinburgh | Completed | No outcome recorded |
| — | NCT02085317 | Mar 2006 → Nov 2009 | lepromatous leprosy | Curt Treu | Completed | No outcome recorded |
| — | NCT00184847 | Mar 2005 → ? | ischemic disease | Radboud University Medical Center | Suspended | No outcome recorded |
| Comparator or background therapy11 trials | ||||||
| Phase 1 | NCT03462017 Background | Mar → Dec 2018 | coronary microvascular disorder | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT04744636 Background | Apr 2017 → Sep 2018 | type 2 diabetes mellitus | Servier | Completed | No outcome recorded |
| Phase 1 | NCT00250185 Background | Nov 2005 → Jun 2007 | limb ischemia | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 1/2 | NCT01242306 Comparator | Mar → Nov 2009 | — | Azienda Ospedaliera San Camillo Forlanini | Completed | No outcome recorded |
| Phase 1/2 | NCT00453531 Background | Mar 2007 → Feb 2009 | limb ischemia | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 2 | NCT03446612 Background | Jan → May 2019 | anemia | GlaxoSmithKline | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00001870 Background | Jan 1999 → Dec 2004 | diabetes mellitus | National Center for Complementary and Integrative Health (NCCIH) | Completed | No outcome recorded |
| — | NCT04918563 Comparator | Sep 2020 → Apr 2021 | mouth mucosa disorder | Semmelweis University | Completed | No outcome recorded |
| — | NCT01075776 Background | Jan 2020 → Jan 2022 | ischemic disease | Queen Mary University of London | Withdrawn | No outcome recorded Stop: Business |
| — | NCT02034331 Comparator | Dec 2012 → Dec 2015 | insulin-resistance syndrome type B, spinal cord injury | James J. Peters Veterans Affairs Medical Center | Completed | No outcome recorded |
| — | NCT00253929 Background | Nov 2005 → Feb 2006 | — | Radboud University Medical Center | Completed | No outcome recorded |
Evidence & citations 16 cited values
Every value below carries the sentence it was read from. 44 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Acetylcholine | “After a baseline period, all three sites will undergo tests of blood vessel function including an acetylcholine dose-response protocol and a test of maximal skin blood flow...” NCT06911372 ↗41“Agonists include: ATP, Bradykinin (BK), Isoproterenol (ISO), and Acetylcholine (Ach), will be infused 3 times each (order randomized).” NCT02833207 ↗ “* Acetylcholine : administered subcutaneously (by iontophoresis) to assess maximal vascular endothelial function.” NCT04744636 ↗ “acetylcholine (endothelium-dependent vasodilator that does not release tPA) at 5, 10 and 20 µg/min” NCT04374500 ↗ |
| Known as | ACETYLCHOLINE CHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL667 ↗ |
| Known as | Acetylcholine chloride for injection | ChEMBL registry synonym — accepted as the source's own label CHEMBL667 ↗ |
| Known as | ACETYLCHOLINE IODIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL667 ↗ |
| Known as | ACh | “The aims of this study were to, after measurement by polarized reflectance spectroscopy (PRS), use pharmacodynamic dose-response analysis on responses to different...” PMID 35449189 ↗ Apr 20221“ACh (Acetylcholine - Sigma-Aldrich, St. Louis, USA) was delivered” NCT02085317 ↗ |
| Known as | Chlorure d'acetylcholine | ChEMBL registry synonym — accepted as the source's own label CHEMBL667 ↗ |
| Known as | Choline acetate (ester) chloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL667 ↗ |
| Known as | Cloruro de acetilcolina | ChEMBL registry synonym — accepted as the source's own label CHEMBL667 ↗ |
| Known as | Miochol | ChEMBL registry synonym — accepted as the source's own label CHEMBL667 ↗ |
| Known as | Miochol-e | ChEMBL registry synonym — accepted as the source's own label CHEMBL667 ↗ |
| Known as | Miphtel | ChEMBL registry synonym — accepted as the source's own label CHEMBL667 ↗ |
| Known as | NSC-755845 | ChEMBL registry synonym — accepted as the source's own label CHEMBL667 ↗ |
| Action | Activate | “Muscarinic acetylcholine receptor M3 agonist” CHEMBL667 ↗ |
| Modality | Small molecule | — CHEMBL667 ↗ |
| Route | Other | “will be injected” NCT00072826 ↗ |
| Target | CHRM3 | “Muscarinic acetylcholine receptor M3 agonist” CHEMBL667 ↗ |